Entries by BioSpace

,

Will Pfizer Make a Play for Struggling GlaxoSmithKline?

Almost a year after its $119 billion offer for AstraZeneca PLC (AZN) fell apart in the face of massive opposition from regulators and internal dissent, global drugmaker Pfizer Inc. (PFE) is once again being floated as a potential buyer of another marquee-name British pharmaceutical company: GlaxoSmithKline (GSK). A column in The Telegraph today said that […]

Merck & Co. Poised To Enter Oral HCV Market Dominated by Gilead and AbbVie

Merck & Co., Inc. (MRK), announced yesterday the first data from the company’s Phase II/III clinical trial dubbed C-SURFER for a once-daily treatment for patients with advanced chronic kidney disease (CKD) that are also infected with chronic hepatitis C virus (HCV) genotype 1 (GT1). The C-SURFER trial demonstrated that a 12-week regimen of NS3/4A protease […]

,

Innate Pharma Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC

Marseille, France-based Innate Pharma announced today that it had inked a co-development and commercialization deal with AstraZeneca (AZN) and MedImmune. MedImmune is a wholly owned subsidiary of AstraZeneca. The deal will focus on pushing the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune. The compound, […]

,

Perrigo Rejects $30B Mylan Bid, Says Deal “Substantially Undervalues” Irish Firm

Pittsburgh, Penn.-based Mylan Inc. (MYL)’s $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) has been rejected by the company, after Perrigo said late Tuesday that the offer “substantially undervalues” Perrigo and “its future growth prospects and “is not in the best interests of Perrigo’s shareholders.” “Perrigo has a long history of driving above […]

,

Amgen Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars

Thousand Oaks, Calif.-based Amgen (AMGN) announced stellar first quarter revenues yesterday, deflecting a failed asthma clinical trial. The company announced a total revenue increase of 11 percent for the first quarter of 2015 compared to the same period last year, rising from $4.521 billion to $5.033 billion. Revenues were driven by sales of Enrel, Prolia, […]

,

Curadev Wrangles a $555 Million Pact With Drug Giant Roche

Swiss drugmaker Roche (RHHBY) is doubling down on its immunotherapy oncology pipeline, on Monday announcing it will pay Indian company Curadev Pharma up to $555 million to develop and market its IDO1 and TDO inhibitors IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) are enzymes that mediate cancer-induced immune suppression, which tumor cells and a certain […]

,

Long Term, Regular Aspirin Use May Reduce Cancer Risk, Harvard School of Public Health Study

Long-term, Regular Aspirin Use Modestly Decreased Cancer Risk PHILADELPHIA — Long-term, regular aspirin use was associated with a modestly reduced overall risk for cancer driven primarily by a reduction in the risk for colorectal cancers, according to research presented here at the AACR Annual Meeting 2015 , April 18-22. “Previous studies of aspirin and cancer […]